clinical trial · NCT03902080
Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
Urovant Sciences GmbH·phase3·completed·n = 1,105
Overactive BladderVibegronPlacebo
brief summary
This study will assess the efficacy of vibegron compared with placebo in men with overactive bladder (OAB) symptoms on pharmacological therapy for benign prostatic hyperplasia (BPH) as defined by micturition and urgency episodes.
started
Mar 26, 2019
primary completion
Jun 15, 2023
completion
Jun 15, 2023
last updated
Aug 7, 2024
official title
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol